skippy44 schreef:
[quote=Eisbear]
En opnieuw naar beneden na een top van 25 dollar! Net als de vorige keer, gebeurde precies hetzelfde. Belooft weinig goeds, hoop dat jullie op tijd winst hebben genomen! succes verder
[/quote]
After Hours $25.75Change: +13.94 +118.04%Volume: 4,940,870
Hot Stocks To Buy [DNDN]
April 28, 2009 by Hot Stocks To Buy
Original Upgrade to Hot Buy on 4/18/09.
[DNDN] Dendreon stock - Hot stocks to buy entry price: $17 - $18.5 Updated to $24 - $28 04/28/09
* Risk level: 10
* Profit potential: 8
* Price Target = $50
* Very risky in the near term, keep an eye on April 28th 2:20pm (CT)
Data from IMPACT trails are successful we are upgrading DNDN to a Super Hot Buy. Price target in the short term is now $60 and long term is now set to $150 (Possible stock split by Mid Summer.)
On April the 16th we added Dendreon Corp. (DNDN) to our hot stocks to buy portfolio at the price of $18.15. Below you will see a few pointers as to why we have chosen to add Dendreon to our list of Hot Stock to buy. We’ve followed this stock for years and feel this is a great time to enter into the stock for those who have missed the previous purchase price of below $5. The recent news on Dendreon’s IMPACT results is just what the company needed and if the details on the news is as expected, this stock can see a rise to above $35 in the short term. Please also consider the risk that if Dendreon’s news on the 14th of April is revealed to be misleading, this stock can take a massive plunge back to below $5.
* Upgraded to from Sell to HOLD by Rodman & Renshaw on April 14th, 2009
* Upgraded by from Mkt Perform to Mkt Outperform by Brean Murray on April 16th, 2009
* Potential buyout candidate by big pharma (possibly Merck)
* On April 14th Dendreon issued a press release announcing that the pivotal Phase 3 IMPACT study of Provenge in men with advanced prostate cancer met its primary endpoint of improving overall survival compared to placebo control.
* On April 28th (2:20pm CT)the results from the IMPACT studies will be presented during a plenary session at the American Urological Association’s Annual Meeting
* Dendreon’s other drug Neuvenge is on the horizon
Hot Stock to Buy recommends taking a small holding in Dendreon and increasing the holding on any non news related dips in the next week. Dendreon is an extremely high risk stock with high potential in the near term. Price target within 6 months is $50.
www.hotstockstobuy.com/2009/04/hot-st...En succes al de longs die hier van in de beginne van dit draadje in het verhaal zitten en er nu ook eens voor beloond worden!
Mvg,
Skip